Results 1 to 10 of about 1,416 (129)

Pruebas funcionales en esclerosis múltiple y su comparabilidad con los valores de administración autónoma: estudio piloto [PDF]

open access: yesBiomédica: revista del Instituto Nacional de Salud, 2023
Introducción. El deterioro neurológico en la esclerosis múltiple es variable para cada paciente y su cuantificación se dificulta con el tiempo. El Multiple Sclerosis Outcome Assessment Consortium estableció medidas clínicas sensibles, costo-efectivas y ...
Laura Estefanía Arenas-Vargas   +2 more
doaj   +2 more sources

Consecuencias sociolaborales del confinamiento por la COVID-19 en pacientes con esclerosis múltiple en dos poblaciones muy diferentes [PDF]

open access: yesNeurología, 2021
Resumen: El confinamiento debido a la pandemia de la COVID-19, realizado a nivel mundial, ha tenido consecuencias casi siempre negativas en los pacientes con esclerosis múltiple (EM).
G.X. Zhang   +9 more
doaj   +2 more sources

Tratamiento inmunosupresor en pulsos en esclerosis múltiple durante el desescalado de la epidemia por SARS-CoV-2. Algoritmo de seguridad [PDF]

open access: yesNeurología, 2020
Resumen: Introducción: La pandemia por SARS-CoV-2 está condicionando los abordajes diagnósticos, terapéuticos y asistenciales establecidos en esclerosis múltiple (EM). Durante las fases inicial y pico de la epidemia, los fármacos modificadores del curso
G. Valero-López   +10 more
doaj   +2 more sources

Natalizumab para la esclerosis múltiple remitente-recurrente

open access: yesNeurología, 2011
Resumen: Introducción: Natalizumab es un anticuerpo monoclonal inhibidor de la migración leucocitaria a través de la barrera hematoencefálica, autorizado para el tratamiento de la esclerosis múltiple remitente-recurrente. Objetivo: Realizar una revisión
A. Horga, M. Tintoré
exaly   +3 more sources

HERV-W association with serum biomarkers NfL and GFAP in multiple sclerosis [PDF]

open access: yesFrontiers in Immunology
BackgroundSerum biomarkers of multiple sclerosis (MS), such as glial fibrillary acidic protein (sGFAP) and neurofilament light chain (sNfL), are established indicators of disease progression and disability.
Stefano Ruberto   +11 more
doaj   +2 more sources

Differential distribution of antiviral serology across multiple sclerosis phenotypes and its implications for disease pathogenesis [PDF]

open access: yesScientific Reports
Multiple sclerosis (MS) is a heterogeneous inflammatory disease of the central nervous system in which environmental factors, particularly viral infections, are thought to contribute to disease susceptibility and progression.
Dominguez-Mozo Maria Inmaculada   +15 more
doaj   +2 more sources

Social and professional consequences of COVID-19 lockdown in patients with multiple sclerosis from 2 very different populations

open access: yesNeurología (English Edition), 2021
The global lockdown measures implemented due to the COVID-19 pandemic have nearly always had negative consequences for patients with multiple sclerosis (MS). Objective: We compared the social and professional effects of confinement on patients with MS in
G.-X. Zhang   +9 more
doaj   +1 more source

Experience with tocilizumab in patients with neuromyelitis optica spectrum disorders

open access: yesNeurología (English Edition), 2022
Introduction: Neuromyelitis optica spectrum disorders (NMOSD) are immune-mediated inflammatory disorders of the central nervous system involving astrocytes, B lymphocytes, anti-aquaporin 4, and such inflammatory mediators as interleukin-6.
E. Carreón Guarnizo   +7 more
doaj   +1 more source

Fe de errores a “Tratamiento inmunosupresor en pulsos en esclerosis múltiple durante el desescalado de la epidemia por SARS-CoV-2. Algoritmo de seguridad” [Neurologia. 2020;35(6):357–362] [PDF]

open access: yesNeurología, 2020
G. Valero-López   +10 more
doaj   +2 more sources

Effect of visual biofeedback cycling training on gait in patients with multiple sclerosis

open access: yesNeurología (English Edition), 2020
Introduction: Gait alterations are present in a high percentage of patients with multiple sclerosis (MS). They appear from early stages of the disease and can limit patients’ capacity to perform basic activities of daily living, affecting their quality ...
A. Hochsprung   +4 more
doaj   +1 more source

Home - About - Disclaimer - Privacy